Switzerland
  • Europe
    • FR
    • DE
    • IT
    • ES
    • BE
    • NL
    • LU
    • DK
    • PL
    • UK
  • Switzerland
    • Basel
    • Bern
    • Geneva
    • Lausanne
    • Zürich
  • Schweiz
  • Suisse
  • Alps
  • Business
    • ABB
    • Chubb
    • Glencore
    • Nestlé
    • Novartis
    • Roche
    • UBS
    • Vitol
    • Zurich Insurance
  • NATO
  • US
  • UK
  • Africa
  • Afrique
  • CH

Categories

  • ABB
  • Alps
  • Basel
  • Bern
  • Chubb
  • Geneva
  • Glencore
  • Lausanne
  • Nestlé
  • Novartis
  • Roche
  • Switzerland
  • UBS
  • Vitol
  • Zürich
  • Zurich Insurance
Switzerland
  • Europe
    • FR
    • DE
    • IT
    • ES
    • BE
    • NL
    • LU
    • DK
    • PL
    • UK
  • Switzerland
    • Basel
    • Bern
    • Geneva
    • Lausanne
    • Zürich
  • Schweiz
  • Suisse
  • Alps
  • Business
    • ABB
    • Chubb
    • Glencore
    • Nestlé
    • Novartis
    • Roche
    • UBS
    • Vitol
    • Zurich Insurance
  • NATO
  • US
  • UK
  • Africa
  • Afrique
  • CH
AstraZeneca–Bristol Myers Squibb merger 'is not highly likely to happen,' says UBS' Michael Yee
UUBS

AstraZeneca–Bristol Myers Squibb merger ‘is not highly likely to happen,’ says UBS’ Michael Yee

  • 2026-08-04

ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email

Michael Yee, UBS global head of biotech research, joins ‘Squawk on the Street’ to discuss the potential mega-merger between UK pharmaceutical company AstraZeneca and its U.S. competitor Bristol Myers Squibb and more.

03:55

Mon, Aug 3 20261:12 PM EDT

  • Tags:
  • AstraZeneca PLC
  • Breaking News: Markets
  • Bristol-Myers Squibb Co
  • business news
  • Markets
  • Neutral
  • Pharmaceuticals
  • Stock markets
  • UBS
Switzerland
www.europesays.com